Table 4.

Summary of adverse events possibly or probably related to MOD-4023 treatment.

	Stage A			Stage B
	Cohort 2 37% weekly	Cohort 3 55.5% weekly	Cohort 1A 123.4% weekly	61.7% weekly
No. of patients	13	13	13	43
No. of patients with any AEs	5	3	6	20
No. of AEs	1	3	8	5
Nausea	0	0	1	0
Fatigue	0	0	1	0
Pain in extremity	0	0	1	0
Headache	0	0	3	2
Dizziness	0	0	1	0
Insomnia	0	0	1	0
Face edema	0	1	0	0
Peripheral edema	0	1	0	0
Hypertension	0	1	0	0
Increased blood glucose	0	0	0	1
Increased glycosylated hemoglobin	0	0	0	0
Decreased hemoglobin	0	0	0	1
Decreased WBC count	1	0	0	0
Increased free thyroxine	0	0	0	1